<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5663">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109056</url>
  </required_header>
  <id_info>
    <org_study_id>192371-019</org_study_id>
    <nct_id>NCT01109056</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of Cyclosporine Ophthalmic Emulsion 0.05%
      (RESTASIS®) in patients with primary pterygium (abnormal growth on surface of eye).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Pterygium Hyperemia Responders at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of pterygium hyperemia responders at Week 16 as measured by the Pterygium Hyperemia Grading Scale. The Pterygium Hyperemia Grading Scale is a 6-point scale (0=absent, 1=trace, 2=mild, 3=moderate, 4=moderately severe, 5=severe). A responder is defined as a patient demonstrating at least a 2-grade decrease from baseline in pterygium hyperemia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Severity Grade of Pterygium Hyperemia at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline in Severity Grade of Pterygium Hyperemia at Week 16. The Pterygium Hyperemia Grading Scale is a 6-point scale (0=absent, 1=trace, 2=mild, 3=moderate, 4=moderately severe, 5=severe). A negative number change from baseline is an improvement and a positive number change from baseline is a worsening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ocular Surface Disease Index© (OSDI©) Questionnaire Score at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in Ocular Surface Disease Index© (OSDI©) Questionnaire score at Week 16. The OSDI© is a 12-question survey for patients to document their dry eye disease symptoms. Each question is rated on a 5-point scale (0=none of the time and 4 = all of the time). The scores are totaled over the 12 questions and normalized/converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Pterygium</condition>
  <arm_group>
    <arm_group_label>cyclosporine ophthalmic emulsion 0.05%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine ophthalmic emulsion 0.05%</intervention_name>
    <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
    <arm_group_label>cyclosporine ophthalmic emulsion 0.05%</arm_group_label>
    <other_name>RESTASIS®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a pterygium in at least one eye that has not been previously removed with
             surgery

        Exclusion Criteria:

          -  Uncontrolled systemic disease

          -  Active eye disease

          -  Current or anticipated use of topical eye medications other than artificial tears.

          -  Anticipated wearing of contact lenses
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <lastchanged_date>May 22, 2012</lastchanged_date>
  <firstreceived_date>April 19, 2010</firstreceived_date>
  <firstreceived_results_date>May 22, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cyclosporine Ophthalmic Emulsion 0.05%</title>
          <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cyclosporine Ophthalmic Emulsion 0.05%</title>
          <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="57"/>
                <measurement group_id="B2" value="58"/>
                <measurement group_id="B3" value="115"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;45 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 45 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="36"/>
                <measurement group_id="B2" value="36"/>
                <measurement group_id="B3" value="72"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="39"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="76"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Pterygium Hyperemia Responders at Week 16</title>
        <description>Number of pterygium hyperemia responders at Week 16 as measured by the Pterygium Hyperemia Grading Scale. The Pterygium Hyperemia Grading Scale is a 6-point scale (0=absent, 1=trace, 2=mild, 3=moderate, 4=moderately severe, 5=severe). A responder is defined as a patient demonstrating at least a 2-grade decrease from baseline in pterygium hyperemia.</description>
        <time_frame>Week 16</time_frame>
        <safety_issue>No</safety_issue>
        <population>Modified Intent to Treat:
All randomized patients who received study treatment and had a baseline and at least one post-baseline assessment of pterygium hyperemia</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine Ophthalmic Emulsion 0.05%</title>
            <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Pterygium Hyperemia Responders at Week 16</title>
            <description>Number of pterygium hyperemia responders at Week 16 as measured by the Pterygium Hyperemia Grading Scale. The Pterygium Hyperemia Grading Scale is a 6-point scale (0=absent, 1=trace, 2=mild, 3=moderate, 4=moderately severe, 5=severe). A responder is defined as a patient demonstrating at least a 2-grade decrease from baseline in pterygium hyperemia.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Severity Grade of Pterygium Hyperemia at Week 16</title>
        <description>Change from Baseline in Severity Grade of Pterygium Hyperemia at Week 16. The Pterygium Hyperemia Grading Scale is a 6-point scale (0=absent, 1=trace, 2=mild, 3=moderate, 4=moderately severe, 5=severe). A negative number change from baseline is an improvement and a positive number change from baseline is a worsening.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <safety_issue>No</safety_issue>
        <population>Modified Intent to Treat:
All randomized patients who received study treatment and had a baseline and at least one post-baseline assessment of pterygium hyperemia</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine Ophthalmic Emulsion 0.05%</title>
            <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Severity Grade of Pterygium Hyperemia at Week 16</title>
            <description>Change from Baseline in Severity Grade of Pterygium Hyperemia at Week 16. The Pterygium Hyperemia Grading Scale is a 6-point scale (0=absent, 1=trace, 2=mild, 3=moderate, 4=moderately severe, 5=severe). A negative number change from baseline is an improvement and a positive number change from baseline is a worsening.</description>
            <units>Scores on a Scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.1" spread="0.35"/>
                  <measurement group_id="O2" value="3.2" spread="0.37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Week 16</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.7" spread="0.76"/>
                  <measurement group_id="O2" value="-0.8" spread="0.75"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Ocular Surface Disease Index© (OSDI©) Questionnaire Score at Week 16</title>
        <description>Change from baseline in Ocular Surface Disease Index© (OSDI©) Questionnaire score at Week 16. The OSDI© is a 12-question survey for patients to document their dry eye disease symptoms. Each question is rated on a 5-point scale (0=none of the time and 4 = all of the time). The scores are totaled over the 12 questions and normalized/converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <safety_issue>No</safety_issue>
        <population>Modified Intent to Treat: All randomized patients who received study treatment and had a baseline and at least one post-baseline assessment of pterygium hyperemia</population>
        <group_list>
          <group group_id="O1">
            <title>Cyclosporine Ophthalmic Emulsion 0.05%</title>
            <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Ocular Surface Disease Index© (OSDI©) Questionnaire Score at Week 16</title>
            <description>Change from baseline in Ocular Surface Disease Index© (OSDI©) Questionnaire score at Week 16. The OSDI© is a 12-question survey for patients to document their dry eye disease symptoms. Each question is rated on a 5-point scale (0=none of the time and 4 = all of the time). The scores are totaled over the 12 questions and normalized/converted to a score of 0-100 (0=no disability and 100=complete disability). A negative number change from baseline represents an improvement.</description>
            <units>Scores on a Scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.2" spread="16.97"/>
                  <measurement group_id="O2" value="29.3" spread="26.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Week 16</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.1" spread="14.95"/>
                  <measurement group_id="O2" value="-10.5" spread="16.02"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Population was used to calculate the number of participants at risk for SAEs and AEs, and is defined as all randomized and treated patients.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cyclosporine Ophthalmic Emulsion 0.05%</title>
          <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>One drop in the study eye (or eyes) administered four times daily (QID)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Meningioma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian Adenoma</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
